Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial

See original here:
CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress.

Read more:
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor -

Go here to see the original:
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022

Continue reading here:
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

Follow this link:
OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Josh Allen, Ph.D., Chief Technology Officer of Imipridones, will participate in a panel discussion hosted by Maxim Group. The event, “Exploring New Targets for Pediatric Brain Cancer,” will take place on Thursday, May 19, 2022 at 9:00 a.m. ET.

Follow this link:
Chimerix to Participate in Maxim Group Panel Discussion

Montrouge, France, May 12, 2022

See the original post:
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update.

Read more from the original source:
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end

More:
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

See the rest here:
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine -

Continued here:
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery...

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022

Continued here:
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.

Read more:
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

?   UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity

Read the original here:
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022

Originally posted here:
Day One Reports First Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2022.

Excerpt from:
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development

More here:
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology...

Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy.

See the original post here:
Addex Announces Participation in the 22nd Bio€quity Europe Conference

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute. Dr. Fry, a world-renowned expert in chimeric antigen receptor T cell (CAR T) therapies, has devoted part of his time to the University of Colorado as a clinical professor of pediatric oncology since joining Sana. He continues to work in his current Sana role without change while serving as the Institute’s Executive Director.

Read more:
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Read more here:
Avicanna Reports Q1 2022 Financial Statement and Management Change